Last reviewed · How we verify
NCT04904419
Multi-center Research Project for Glioma Molecular Pathology Intraoperative Rapid Detection
trial testing Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e in Glioma, Malignant in 137 participants. Completed in 31 January 2022.
31 January 2022
Quick facts
| Lead sponsor | Jinsong Wu |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 137 |
| Start date | 1 August 2021 |
| Primary completion | 31 January 2022 |
| Estimated completion | 31 January 2022 |
| Sites | 4 locations across China |
Drugs / interventions tested
- Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
Conditions studied
- Glioma, Malignant — all drugs for Glioma, Malignant →
Sponsor
Jinsong Wu
Who can join
Adults 18 to 80, any sex, with Glioma, Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We explores the accuracy and sensitivity of rapid intraoperative detection of IDH, TERT, BRAF indicators through a prospective clinical multi-center study. This part includes a total of 300 fresh tissue samples, paired blood samples, relevant clinical information and follow-up information from 300 patients with different grades of adult glioma. By comparing with the postoperative sequencing results, the specificity and sensitivity of intraoperative IDH and TERT rapid detection results are clear.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ferroptosis as a potential therapeutic target for obesity-related metabolic diseases.
Huang CD, Luo T, Zhang H, Cheng LH, et al · · 2025 · cited 2× · PMID 40689204 · DOI 10.3389/fphar.2025.1581632 -
Rapid diagnosis of adult-type diffuse glioma using a layered scheme.
Wu J, Wu S, Cao D, Xiong Z, et al · · 2025 · PMID 40457320 · DOI 10.1186/s12916-025-04124-9
Verify or expand the search:
- PubMed search for NCT04904419
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioma, Malignant
Currently open trials in the same condition.
- NCT06917885 — CUE-102 in Recurrent Glioblastoma · Phase 1 · recruiting
- NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
- NCT06169280 — Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma · Phase 1 · recruiting
- NCT06636162 — Window of Opportunity Study of DSP-0390 in Gliomas · EARLY_PHASE1 · recruiting
- NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
Other Jinsong Wu trials
Trials by the same sponsor.
- NCT04924127 — Molecular Pathology Research Project of Glioma · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04904419 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jinsong Wu
- Last refreshed: 18 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04904419.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing